QVAR 40 Drug Patent Profile

When do Qvar 40 patents expire, and when can generic versions of Qvar 40 launch?

Qvar 40 is a drug marketed by Teva Branded Pharm and is included in one NDA. There are five patents protecting this drug.

The generic ingredient in QVAR 40 is beclomethasone dipropionate. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the beclomethasone dipropionate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Qvar 40

A generic version of QVAR 40 was approved as beclomethasone dipropionate by AMNEAL IRELAND LTD on December 16^th, 2025.

Summary for QVAR 40

US Patents:	5
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	5,078
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for QVAR 40
DailyMed Link:	QVAR 40 at DailyMed

US Patents and Regulatory Information for QVAR 40

QVAR 40 is protected by five US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No			Y		Y
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No			Y		Y
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No			Y		Y
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No			Y		Y
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000		DISCN	Yes	No			Y		Y

Expired US Patents for QVAR 40

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000
Teva Branded Pharm	QVAR 40	beclomethasone dipropionate	AEROSOL, METERED;INHALATION	020911-002	Sep 15, 2000

International Patents for QVAR 40

When does loss-of-exclusivity occur for QVAR 40?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hong Kong

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

San Marino

Serbia

Slovenia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering QVAR 40 around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2011254958
Brazil	112012029106
Canada	2799625
Canada	2887315
Canada	2936362
Canada	3019694
Canada	3111537

QVAR 40 Market Dynamics, Patent Position, and Financial Trajectory

Last updated: August 17, 2026

QVAR 40 is the 40-mcg-per-actuation strength of beclomethasone dipropionate HFA, an inhaled corticosteroid marketed in the United States by Teva Pharmaceuticals. The product is used for long-term asthma control, not acute bronchospasm relief. Its commercial position has weakened as lower-cost generic inhaled corticosteroids, authorized generics, and competing branded inhalers have expanded.

QVAR 40 remains commercially relevant because it uses a breath-actuated delivery system that does not require the patient to coordinate canister actuation with inhalation. Its financial outlook is constrained by mature therapeutic-class competition, limited product-level disclosure from Teva, payer pressure, and the absence of a large exclusivity event capable of restoring pricing power.

What is QVAR 40 and how is it used?

QVAR 40 contains 40 micrograms of beclomethasone dipropionate per actuation. The current U.S. product is QVAR RediHaler, a breath-actuated inhalation aerosol. It is approved for the maintenance treatment of asthma in patients aged 4 years and older. The product is not indicated for the immediate relief of acute asthma symptoms. [1]

Attribute	QVAR 40
Active ingredient	Beclomethasone dipropionate
Strength	40 mcg per actuation
Dosage form	Metered-dose inhalation aerosol
Current delivery system	QVAR RediHaler
Route	Oral inhalation
U.S. sponsor	Teva Pharmaceuticals
Main indication	Maintenance treatment of asthma
Rescue use	No
Therapeutic class	Inhaled corticosteroid
FDA approval basis	New drug application
Relevant FDA application	NDA 208928 for QVAR RediHaler
Primary market	United States

QVAR RediHaler replaced the earlier QVAR product, which required manual actuation during inhalation. The RediHaler device is breath actuated and does not require shaking or priming before each use according to the prescribing information. [1]

How does QVAR 40 compare with competing inhaled corticosteroids?

QVAR 40 competes in a mature inhaled corticosteroid market where clinical differentiation is modest and formulary access often determines prescribing volume.

Product	Active ingredient	Delivery system	Commercial positioning
QVAR RediHaler	Beclomethasone dipropionate	Breath-actuated HFA inhaler	Device convenience and established brand
Flovent HFA	Fluticasone propionate	Pressurized metered-dose inhaler	Historically large branded franchise; generic and authorized-generic pressure
Flovent Diskus	Fluticasone propionate	Dry-powder inhaler	Device alternative to HFA products
Arnuity Ellipta	Fluticasone furoate	Dry-powder inhaler	Once-daily dosing
Pulmicort Flexhaler	Budesonide	Dry-powder inhaler	Established inhaled corticosteroid franchise
Alvesco	Ciclesonide	HFA inhaler	Differentiated prodrug positioning
Generic budesonide and fluticasone	Various	Various	Lower-cost formulary options

QVAR’s strongest commercial attributes are its breath-actuated device and established pediatric use. Its main weaknesses are the maturity of beclomethasone as an active ingredient, lack of once-daily dosing differentiation, and the availability of generic or lower-cost alternatives.

The device may be valuable for patients who have difficulty coordinating inhalation with actuation. That advantage does not automatically translate into broad formulary preference. Pharmacy benefit managers generally prioritize net price, rebate economics, generic substitution, and total treatment cost.

What is the FDA regulatory status of QVAR 40?

QVAR RediHaler is an FDA-approved maintenance asthma treatment. Its labeled age range begins at 4 years. The product is available in 40-mcg and 80-mcg strengths. The 40-mcg strength is generally used as a lower-strength maintenance option, with dosing adjusted according to disease severity and prior corticosteroid exposure. [1]

The key regulatory distinctions are:

1. QVAR 40 is a controller medicine, not a rescue inhaler.
2. It is an inhaled corticosteroid monotherapy, not a corticosteroid/long-acting bronchodilator combination.
3. The RediHaler device is integral to the commercial product because the delivery mechanism differentiates it from conventional manually actuated inhalers.
4. FDA approval of a generic active ingredient does not necessarily establish substitutability for the RediHaler device.

For inhaled products, FDA approval requires evaluation of formulation, device performance, delivered dose, aerodynamic particle size, and comparative performance. Device substitution can therefore be more complex than substitution between conventional oral tablets.

What patents protect QVAR 40?

QVAR 40 is protected primarily through patents and regulatory rights associated with the RediHaler device, formulation, and inhalation system rather than through the basic beclomethasone molecule. Beclomethasone dipropionate is an old active ingredient and does not provide meaningful new-molecule exclusivity for the current product.

The relevant intellectual-property categories include:

• Breath-actuated inhaler mechanics.
• Canister and valve operation.
• Metering and dose delivery.
• Formulation stability.
• Aerosol performance.
• Device operation without manual actuation.
• Manufacturing and assembly methods.

The FDA Orange Book should be used to identify the patents listed against NDA 208928 and to track any changes in listed patent status. The Orange Book, rather than general patent databases, is the controlling commercial reference for assessing whether an abbreviated new drug application applicant must certify to listed patents. [2]

A patent expiration date alone does not establish the earliest legally permissible generic launch date. Launch timing also depends on:

• Whether the challenger filed a Paragraph IV certification.
• Whether Teva sued within the statutory 45-day period.
• Whether an automatic 30-month stay applied.
• Whether the challenger secured a favorable court decision.
• Whether the product is therapeutically substitutable at the pharmacy level.
• Whether the device claims can be designed around.

When does QVAR 40 lose exclusivity?

QVAR 40 has already lost the exclusivity associated with the underlying beclomethasone molecule. The remaining commercial protection is product-specific and depends on the RediHaler device, formulation, patent listings, and regulatory exclusivity.

Exclusivity layer	QVAR 40 position
New chemical entity exclusivity	Not applicable to beclomethasone
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	Any historical period would have expired
Basic active-ingredient patent	Expired or commercially irrelevant
Device and formulation patents	Potentially relevant; status must be assessed in the current Orange Book
Trade dress and branding	Limited protection against therapeutic substitution
FDA approval	Continues unless withdrawn or discontinued

The commercial risk is therefore gradual erosion rather than a single “loss of exclusivity” date. QVAR may experience declining volume and price before every relevant patent expires because payers can shift patients to other inhaled corticosteroids.

Are there Paragraph IV challenges to QVAR 40?

A Paragraph IV challenge is legally possible when an ANDA applicant seeks approval before expiration of an Orange Book-listed patent and certifies that the patent is invalid, unenforceable, or will not be infringed. The practical risk for QVAR RediHaler depends on whether a generic manufacturer can reproduce the device and obtain FDA approval for an equivalent inhaled product.

For conventional beclomethasone inhalers, the main barrier is not the active ingredient. It is the combination of device engineering, aerosol performance, product characterization, and substitutability.

The key competitive scenarios are:

Scenario	Market effect
Generic conventional beclomethasone inhaler	Price pressure on the beclomethasone category, but potentially limited direct substitution
Generic or authorized generic RediHaler-equivalent	High direct risk to QVAR 40 volume and price
Device-around inhaler	Moderate risk if FDA determines substitutability or physicians accept the alternative
Competing generic fluticasone or budesonide	Indirect pressure through formulary conversion
No direct generic	Continued niche revenue, but with declining net price

Public information does not support treating QVAR 40 as insulated from generic risk. It also does not support assuming that a generic beclomethasone product will automatically be pharmacy-substitutable for QVAR RediHaler.

What is the Orange Book status of QVAR 40?

QVAR RediHaler is listed in the FDA Orange Book under Teva’s approved application. The Orange Book is the relevant source for:

• Approved strengths.
• Reference-listed drug status.
• Patent listings.
• Use codes.
• Patent certification requirements.
• Approved dosage forms and routes.

QVAR’s patent analysis should be conducted at the NDA and strength level rather than by searching only for “beclomethasone.” A molecule-level search produces an incomplete risk assessment because the most relevant claims may attach to the inhaler system or formulation.

The Orange Book also does not capture every commercial constraint. It does not fully address trade secrets, manufacturing know-how, device tooling, supply agreements, or the practical difficulty of producing a reliable aerosol product at scale.

What formulation and manufacturing barriers protect QVAR 40?

The principal technical barriers are delivery-system barriers. A successful competitor must control the interaction among the drug suspension, propellant, container, valve, actuator, and breath-actuation mechanism.

Important manufacturing and IP considerations include:

• Uniform dose delivery across the labeled canister life.
• Consistent aerosol particle-size distribution.
• Valve reproducibility.
• Moisture and temperature stability.
• Compatibility between formulation and container components.
• Device activation at different inhalation flow rates.
• Reliable operation after storage and repeated use.
• Demonstration of in vitro equivalence.
• Commercial-scale assembly and quality control.

These requirements can delay generic entry even where the active ingredient is old. They also create potential licensing value for device patents, manufacturing know-how, and component supply arrangements.

Which companies compete with QVAR 40?

QVAR competes against multinational pharmaceutical companies and generic manufacturers across the inhaled corticosteroid category.

The main branded competitors include:

• GSK, through Flovent and other respiratory products.
• AstraZeneca, through Pulmicort and related respiratory therapies.
• Organon and other companies involved in respiratory products.
• Covis Pharma, through Alvesco.
• Generic manufacturers supplying budesonide, fluticasone, and other inhaled corticosteroids.

The competitive environment shifted materially after the withdrawal of certain branded respiratory products and the expansion of authorized and generic alternatives. GSK’s Flovent transition created a more price-sensitive market, while generic inhaled corticosteroid availability reduced the ability of mature brands to preserve list-price premiums.

QVAR’s differentiation is strongest when a prescriber values breath actuation or when the patient has poor inhaler coordination. Its differentiation is weakest when a payer imposes a preferred generic or requires step therapy.

What is QVAR 40’s financial trajectory?

Teva does not generally report QVAR 40 revenue as a separate public line item. QVAR is included within broader respiratory or other product categories, preventing a reliable product-level revenue series from public financial statements. [3]

The likely financial trajectory is:

Period	Financial trend
Launch and post-launch period	Revenue supported by conversion from legacy QVAR and device differentiation
Mature branded period	Stable or declining prescriptions with pricing pressure
Generic-expansion period	Lower net price, formulary displacement, and reduced branded volume
Late-life period	Niche revenue from loyal users, pediatric use, and device-preference segments
Post-patent competitive period	Potential rapid erosion if a directly substitutable RediHaler-type product launches

QVAR’s revenue quality is weaker than that of a protected specialty medicine because the product operates in a crowded maintenance market and has no exclusivity tied to a new chemical entity. The product can still produce cash flow, but it is unlikely to be a major growth driver for Teva without pricing improvement, broader formulary access, or an expanded respiratory strategy.

The largest financial variables are:

1. Net price after rebates and discounts.
2. Preferred formulary status.
3. Direct generic entry.
4. Patient retention on the breath-actuated device.
5. Teva’s manufacturing cost and supply reliability.
6. Competitive generic pricing in fluticasone and budesonide.
7. Pediatric and low-coordination patient demand.

What generic launch risks exist for QVAR 40?

The highest-risk launch would be an FDA-approved product that replicates the RediHaler’s breath-actuated operation and is accepted as therapeutically equivalent. Such a product could trigger rapid substitution, depending on state pharmacy laws and FDA product-rating treatment.

A conventional beclomethasone inhaler would create a lower direct threat but could still pressure QVAR through physician prescribing and payer formulary changes. The broader inhaled corticosteroid class is already exposed to generic competition, making QVAR vulnerable to indirect switching.

A plausible launch sequence would be:

1. An ANDA applicant develops an equivalent or near-equivalent inhaler.
2. The applicant files patent certifications, potentially including Paragraph IV.
3. Teva evaluates infringement and may initiate patent litigation.
4. FDA review addresses device, formulation, and performance equivalence.
5. A court settlement or judgment determines launch timing.
6. Payers decide whether the product receives preferred status.
7. Substitution and physician switching determine actual erosion.

The patent case outcome would not alone determine commercial success. Formulary placement and manufacturing capacity would be equally important.

Does biosimilar risk affect QVAR 40?

No. QVAR 40 is a small-molecule inhaled drug-device combination, not a biologic. Biosimilar approval pathways do not apply. The relevant competitive pathways are ANDAs, potential 505(b)(2) applications, device-specific FDA requirements, and state substitution rules.

What licensing deals affect QVAR 40?

QVAR’s commercial history is linked to Teva’s acquisition of the 3M respiratory business, which brought QVAR and other respiratory assets into Teva’s portfolio. The transaction was part of Teva’s broader expansion in respiratory medicine. [4]

No publicly disclosed, product-specific licensing arrangement currently establishes a separate economic participation right in QVAR 40 comparable to a royalty-bearing biotech license. The key commercial relationship is Teva’s ownership and marketing of the product.

Any assessment of third-party rights should separate:

• Historical acquisition rights.
• Device and formulation patents.
• Component supply agreements.
• Manufacturing arrangements.
• Distribution agreements.
• Product-specific royalty obligations.

What litigation affects QVAR 40?

QVAR-related litigation risk is primarily patent litigation involving ANDA applicants and the RediHaler device or formulation. A complete current litigation determination requires review of federal court dockets, FDA Paragraph IV notices, and Orange Book updates.

The commercially relevant litigation questions are:

• Whether a challenger has filed an ANDA.
• Which listed patents were certified against.
• Whether Teva filed suit within 45 days.
• Whether a 30-month stay applies.
• Whether the asserted claims cover the accused device.
• Whether a settlement permits an earlier launch.
• Whether the challenger can launch “at risk.”

A generic entry date should not be estimated from a patent expiration date alone. Litigation, settlement terms, claim construction, and FDA approval timing can materially change the outcome.

How strong is the QVAR 40 patent estate?

QVAR’s estate is moderately differentiated technically but limited economically by the age of the active ingredient and the availability of alternative inhaled corticosteroids.

Factor	Assessment
Active ingredient protection	Weak or expired
Device differentiation	Meaningful
Formulation complexity	Meaningful
Manufacturing barriers	Moderate to high
Clinical differentiation	Moderate for selected patients
Payer protection	Limited
Generic substitution risk	Moderate to high
Revenue durability	Moderate in niche segments; weak as a broad growth asset

The strongest protection relates to the device and delivery system. The weakest protection relates to the molecule itself and the broader asthma indication.

Key Takeaways

• QVAR 40 is Teva’s 40-mcg breath-actuated beclomethasone inhaler for maintenance asthma treatment.
• Its commercial differentiation comes from the RediHaler device, not from the old active ingredient.
• Teva does not publicly disclose reliable standalone QVAR 40 revenue.
• The product faces direct risk from a RediHaler-equivalent generic and indirect risk from generic fluticasone and budesonide.
• Orange Book patents, not molecule-level patent searches, are central to launch-risk analysis.
• Patent expiry is unlikely to produce a single cliff unless a directly substitutable generic reaches the market.
• Manufacturing, aerosol performance, device equivalence, and formulary access are major barriers to entry.
• Biosimilar risk is irrelevant because QVAR 40 is not a biologic.
• The financial outlook is mature to declining, with residual value concentrated in device-preference, pediatric, and low-coordination patient segments.

FAQs About QVAR 40 Market and Patent Risk

Is QVAR 40 the same as QVAR RediHaler?

QVAR 40 identifies the 40-mcg strength. The current U.S. branded product is QVAR RediHaler, which uses a breath-actuated inhaler.

Is QVAR 40 stronger than albuterol?

QVAR 40 and albuterol have different purposes. QVAR is a maintenance corticosteroid. Albuterol is a short-acting bronchodilator used for rapid symptom relief.

Can QVAR 40 be replaced automatically by generic beclomethasone?

Automatic substitution depends on the FDA equivalence rating, product presentation, state law, and payer policy. A generic beclomethasone inhaler is not automatically interchangeable with a breath-actuated QVAR RediHaler product.

Does QVAR 40 have blockbuster revenue potential?

Its mature class, generic exposure, and lack of new-molecule exclusivity make blockbuster growth unlikely. The product’s value is more consistent with a durable niche respiratory asset than a high-growth franchise.

What is the main due-diligence risk for a QVAR 40 acquisition?

The main risk is direct device-level generic entry combined with formulary displacement. Revenue concentration, patent claim scope, Orange Book listings, manufacturing capacity, and payer access should be evaluated together.

References

1. U.S. Food and Drug Administration. (2023). QVAR RediHaler prescribing information. Teva Respiratory, LLC.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Teva Pharmaceutical Industries Ltd. (2024). Annual report on Form 20-F for the year ended December 31, 2023. https://ir.tevapharm.com/

4. Teva Pharmaceutical Industries Ltd. (2006). Teva completes acquisition of IVAX and expands respiratory portfolio through 3M respiratory business transaction. Teva Pharmaceuticals.